PROM1 and cholangiocarcinoma: The therapeutic targeting potential of CD133 was evaluated for advanced cholangiosarcoma, in a phase 2 clinical trial (NCT02541370) (CCA), and using an immunotherapeutic approach based on CAR-T cells (chimeric antigen receptor T cells) that were transduced with the anti-CD133 (CD133 CAR-T) and anti-EGFR (epidermal growth factor receptor) (CART-EGFR).